iBio, Inc. (IBIO) Dividend History

iBio, Inc. is a biotechnology company that specializes in the development and production of plant-based biopharmaceutical products. Using proprietary plant-based expression systems, the company focuses on creating vaccines, monoclonal antibodies, and other therapeutic proteins. iBio aims to leverage its technology to provide cost-effective and scalable solutions for the development of biologics and vaccines.

Dividend History

iBio, Inc. currently does not pay dividends

Company News

  • iBio and AstralBio Unveil Obesity Program with Novel Amylin Agonist Antibody Demonstrating Promising In Vivo Results

    iBio and AstralBio have developed a novel amylin receptor agonist antibody that significantly reduced acute food intake in a mouse model of obesity, comparable to a leading amylin peptide agonist. The findings support the potential of antibody-based agonists to address the growing demand for safer, longer-acting treatments for obesity and cardiometabolic diseases.

    GlobeNewswire Inc.
  • Balancing Volatility With Stability When Trading Penny Stocks

    Here's how to balance volatility with stability when profiting with penny stocks The post Balancing Volatility With Stability When Trading Penny Stocks appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

    PennyStocks
    Featured Companies: VERB
  • Top 4 Health Care Stocks That May Rocket Higher In Q1

    The most oversold stocks in the health care presents an opportunity to buy into undervalued companies. The RSI is a momentum indicator, which compares a stock's strength on days when prices go up to its strength on days when prices go down. When compared to a stock's price action, it can give traders a better sense of how a stock may perform in the short term. An asset is typically considered oversold when the RSI is below 30, according to Benzinga Pro. Here’s the latest list of major oversold players in this sector, having an RSI near or below 30. iBio, Inc. (NYSE: IBIO) On Dec. 5, iBio announced pricing of a $4.5 million public offering. The company’s stock fell around 11% ...

    Benzinga
    Featured Companies: GRI VYNE
  • iBio (IBIO) Q3 2022 Earnings Call Transcript

    IBIO earnings call for the period ending March 31, 2022.

    The Motley Fool
  • New Strong Sell Stocks for October 29th

    IBIO, POST, INSM, DVA, and BSET have been added to the Zacks Rank #5 (Strong Sell) List on October 29, 2021.

    Zacks Investment Research
    Featured Companies: BSET DVA INSM POST
Page data last updated 07/23/2025 08:49:35 UTC